Cancer vaccines show promise for treatment and prevention
For more than three decades, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center researchers have pursued an ambitious idea: that vaccines could train the immune system to recognize and fight cancer. Now, a landmark phase 3 clinical trial of a personalized melanoma vaccine shows that this approach can improve outcomes for patients. Johns Hopkins Kimmel Cancer Center was among the clinical…
For over three decades, researchers at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center have been investigating the potential of cancer vaccines to train the immune system to recognize and combat cancer. A major phase 3 clinical trial of a personalized melanoma vaccine, conducted at numerous clinical centers including Johns Hopkins Kimmel Cancer Center, has now demonstrated that this approach can enhance patient outcomes.
According to a New England Journal of Medicine editorial, vaccines have been among the most impactful medical innovations, yet efforts to develop vaccines targeting established cancers have historically been unsuccessful. This landmark trial represents a significant turning point for a field that has faced numerous setbacks after decades of fundamental discoveries.
Elizabeth Jaffee, M.D., a leading figure in therapeutic cancer vaccination, emphasized that despite initial skepticism, the scientific community persevered, ultimately uncovering crucial tools to make this treatment successful. The late 1980s saw Johns Hopkins immunologists Elizabeth Jaffee and Daniel Laheru pioneer therapeutic cancer vaccines, using genetically modified tumor cells to stimulate immune responses against cancer.
Their efforts led to early clinical trials for pancreatic cancer, resulting in the generation of organized immune cell clusters within tumors. Subsequent breakthroughs at Johns Hopkins Medicine, including research on PD-1 checkpoint inhibitors and cancer genetics, provided further understanding of why cancer vaccines might be more effective when combined with immunotherapy.
These discoveries laid the groundwork for personalized cancer vaccines, which identify a patient's unique tumor mutations, vaccinate against them to stimulate cancer-specific T cells, and employ checkpoint blockade to maintain immune cell activity. Recent studies have shown encouraging results in personalized vaccines combining with immunotherapy drugs like pembrolizumab, demonstrating activity in hepatocellular carcinoma and fibrolamellar carcinoma.
Additionally, researchers at Johns Hopkins are exploring vaccines targeting KRAS mutations, a genetic alteration present in over 90% of pancreatic cancers, potentially offering a preventive strategy for early-stage disease.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
